Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-527-2 | CAS number: 584-03-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- TBC
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- guideline study with acceptable restrictions
- Remarks:
- The study was conducted to international guideline with some deviations i.e. only 45 days exposure instead of 63 days, no clarity on measurement of estrous cycle or sperm analysis and no T4/T3 measurements were taken.e
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Version / remarks:
- Not specified
- Deviations:
- yes
- Remarks:
- The study was conducted to international guideline with some deviations i.e. only 45 days exposure instead of 63 days, no clarity on measurement of estrous cycle or sperm analysis and no T4/T3 measurements were taken.e
- GLP compliance:
- not specified
- Limit test:
- no
Test material
- Reference substance name:
- Butane-1,2-diol
- EC Number:
- 209-527-2
- EC Name:
- Butane-1,2-diol
- Cas Number:
- 584-03-2
- Molecular formula:
- C4H10O2
- IUPAC Name:
- butane-1,2-diol
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Crj: CD(SD)
- Details on species / strain selection:
- Not stated
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories Japan, Inc.,
- Age at study initiation: Approximately 8 weeks
- Fasting period before study: no
- Housing: Animals were housed in polycarbonate cages (265 W × 426 D × 200 H mm, Tokiwa Kagaku Kikai Co., Ltd.) in which bedding for experimental animals (Betachip, Charles River Laboratories Japan, Inc.) was laid: 2 animals/sex/cage during quarantine and acclimatization period, 1 animal/cage during the premating treatment period, 1 male and 1 female/cage during the mating period, 1 litter/cage during the lactation period. The animals were reared on steel racks (four-tiered).
- Diet (e.g. ad libitum): Autoclaved solid feed for experimental animals (CRF-1, Oriental Yeast Co., Ltd.) was fed ad libitum. Feed was changed at a frequency of once per week. Feed for which the analytical values of residual agricultural chemicals and contaminants were confirmed to be the internal SOP-defined concentrations or less was used.
- Water (e.g. ad libitum): All animals had free access to tap water. Tap water for drinking was filtrated through a 5 μm filter and irradiated by UV light. Water for drinking was changed at a frequency of once per week. Water quality tests in compliance with the Water Supply Law were conducted regularly and the analysis results were confirmed to be within the acceptance criteria as stipulated by the annex of the Ordinance of the Ministry of Health and Welfare No. 56.
- Acclimation period: At least 6 days prior to start of treatment.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20°C to 25°C.
- Humidity (%): 40 - 70%
- Air changes (per hr): 12 times/hour
- Photoperiod (hrs dark / hrs light): 12/12
IN-LIFE DATES: From: Animal arrival August 28, 1991 but date of necropsy was not documented
Administration / exposure
- Route of administration:
- oral: gavage
- Details on route of administration:
- Oral gavaged using a syringe attached to a stomach tube.
- Vehicle:
- water
- Remarks:
- Purified water
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The test article was dissolved in purified water and dosing solutions at the nominal concentrations were prepared. The preparation was conducted once weekly and the dosing solutions were kept refrigerated and protected from light until immediately before dosing.
For stability of the test article in the dosing solution, the dosing solutions for the low dose group and high dose group were analyzed before the commencement of dosing in a laboratory of Mitsubishi Kasei Institute of Toxicological and Environmental Sciences, Co., Ltd., and the test article was confirmed to be stable for 14 days under the storage condition.
DIET PREPARATION: N/A - Rate of preparation of diet (frequency): - Mixing appropriate amounts with (Type of food): - Storage temperature of food: VEHICLE - Justification for use and choice of vehicle (if other than water): N/A
- Concentration in vehicle: The concentrations measured for all dose levels were within ±2% of the nominal concentrations.
- Amount of vehicle (if gavage): The concentrations measured for all dose levels were within ±2% of the nominal concentrations.
- Lot/batch no. (if required): Not stated
- Purity: Not stated. - Analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 42 days for male
40 - 45 day for female - Frequency of treatment:
- Daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Dose / conc.:
- 40 mg/kg bw/day (nominal)
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Dose / conc.:
- 1 000 mg/kg bw/day (nominal)
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- Method: Animals were gavaged using a syringe attached to a stomach tube. Dose volume was 5 mL/kg, and individual volumes were calculated based on the bodyweights measured at the most recent day.
Frequency: Once daily
-F0 males:42 consecutive days
-F0 females: 40 – 45 consecutive days.
-F1 animals: Potential indirect exposure in utero and through the milk during lactation
Dose levels: The amount of test item to be administered was calculated according to the most recent body weight recorded.
Group 1: 0 mg/kg/day
Group 2: 40 mg/kg/day
Group 3: 200 mg/kg/day
Group 4: 1000 mg/kg/day
Administration volume 5 mL/kg
Dosing was administered once daily in the morning to males 14 days prior to mating and during the mating period and thereafter until the day before the planned sacrifice for a total of 42 days and to females from 14 days prior to mating and during the period covering completion of mating and delivery until Lactation Day 3 for a total of 40 to 45 days. For notations of days after the commencement of dosing, the day of commencement of dosing was defined as 0 days after the commencement of treatment, the day when mating was confirmed as Gestation Day 0, and the day after delivery as Lactation Day 1. - Positive control:
- No
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Not specified
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Daily
BODY WEIGHT: Yes
or males, body weights were measured on the day of the commencement of dosing and thereafter once per week. For females, bodyweights were measured on the day of the commencement of dosing and thereafter once per week before mating and after the completion of mating on gestation days 0, 7, 14, and 20, and lactation days 1 and 4.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): Yes
For males, food consumption was measured once per week from the commencement of dosing, except for the mating period. For females, gross weights of food were measured once per week before mating, and after the completion of mating, on gestation days 0, 7, 14, and 20, and Lactation Days 1 and 4.
FOOD EFFICIENCY: No
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 21 hours after completion of treatment
- Anaesthetic used for blood collection: Not specified
- How many animals: All surviving males.
- Parameters checked in table: Yes
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: 21 hours after completion of treatment
- Animals fasted: Yes, but details not disclosed.
- How many animals: All surviving males.
- Parameters checked in table: Yes
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No
IMMUNOLOGY: No
OTHER: Yes (see below);
ESTROUS CYCLE: Yes
- Dry smears - not specified.
- Wet smears - not specified.
THYROID HORMONE ANALYSIS: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- Bartlett's test for homogeneity of variance, when the variances were heterogeneous, the Kruskal-Wallis test was performed. Dunnett’s method in case of an equal number of animals between the groups or using Scheffe’s method in case of a different number of animals between the groups. For count data, the data were tested by Fisher's exact probability test.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- In females of the 1000 mg/kg group, post-treatment decreases in locomotor activity were observed in more than half of the animals and hypopnea in a few animals. Both signs were transient in nature. The number of affected animals decreased over time, and on day 6 or later, the sign occurred only in one animal until gestation day 5 (at 21 days after the commencement of treatment). No abnormalities occurred in males. In addition, hair loss was observed in one female of the 1000 mg/kg group but the finding is considered a spontaneous finding.
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- For glucose in the 40 mg/kg group and total bilirubin in the 200 mg/kg group, statistical differences were noted. However, no related changes suggestive of the effects of the test article were noted.
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Bilateral atrophy of the testes was found in one male of the 1000 mg/kg group (animal number: DM09). In the other animals, no abnormalities were found in either males or females of any groups
- Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- effects observed, non-treatment-related
- Description (incidence and severity):
- In both the control group and 1000 mg/kg group, focal myocardial degeneration in the heart, microgranuloma in the liver, fatty change of hepatocytes, and brown pigmentation in tubular epithelial cells, cyst, focal basophilic change in renal tubules and fatty change of tubular epithelia in the kidneys were sporadically found. No between-group differences in the incidences of these changes were noted; therefore, these changes were not indicative of the treatment effects. In addition, in females, slight increases of hematopoietic cells in the spleen and diffuse chronic hypertrophy in the fascicular zone of the adrenals were found in almost all animals in the control and 1000 mg/kg groups without any between-group differences.
The atrophy of the testes of the male in the 1000 mg/kg found in necropsy was reflected by extensive atrophy of seminiferous tubules found in histopathology. The change was associated with slight bilateral atrophy of the epididymides. In the testes, degeneration, vacuolation, and multinucleated cell formation were observed in the sperm cells, but no abnormalities were observed in Sertoli cells or interstitial cells. In the other animals, including those of the 40 and 200 mg/kg groups, no abnormalities were found in the testes or epididymides. The other changes included germinal center deficiency in the spleen and unilateral extensive hemorrhagic necrosis in the adrenal cortex in one female of the 1000 mg/kg group (D07). - Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not specified
Effect levels
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Target system / organ toxicity
- Key result
- Critical effects observed:
- no
Any other information on results incl. tables
Table 2. Total incidence of clinical signs in male
Dose (mg/kg) |
No. of animals |
Findings |
Days after commencement of treatment |
||||||||||||||||||||
0 |
2 |
4 |
6 |
8 |
10 |
12 |
14 |
16 |
18 |
20 |
22 |
24 |
26 |
28 |
30 |
32 |
34 |
36 |
38 |
41 |
|||
0 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
40 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
200 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
1000 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
RSM: Decrease locomotor activity, -: No signs were observed in any animals, +: Slight
Table 3. Total Incidence of Clinical Signs in Female
Dose (mg/kg) |
No. of animals |
Findings |
Days after commencement of treatment |
Days of gestation |
Days of lactation |
||||||||||||||||||||
0 |
2 |
4 |
6 |
8 |
10 |
12 |
14 |
0 |
2 |
4 |
6 |
8 |
10 |
12 |
14 |
16 |
18 |
20 |
0 |
1 |
2 |
3 |
|||
0 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
40 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
200 |
10 |
RSM (+) Hypopnoea |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
1000 |
10 |
RSM (+) Hypopnoea |
6 - |
3 1 |
2 2 |
2 1 |
2 - |
2 - |
1 1 |
1 1 |
1 1 |
1 1 |
1 1 |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
- - |
RSM: Decrease locomotor activity, -: No signs were observed in any animals, +: Slight, 1) two of the animals did not copulate
Table 4. male group mean body weight values and mean body weight gain.
Dose (mg/kg) |
Group mean body weight |
Mean body weight gain |
|||||||||||
Days after commencement of treatment |
|||||||||||||
0 |
7 |
14 |
21 |
28 |
35 |
41 |
7 |
14 |
21 |
28 |
35 |
41 |
|
0 |
313 |
360 |
400 |
419 |
463 |
470 |
483 |
47 |
87 |
106 |
130 |
157 |
170 |
40 |
315 |
363 |
401 |
420 |
442 |
465 |
480 |
48 |
87 |
105 |
128 |
150 |
165 |
200 |
314 |
358 |
395 |
416 |
438 |
462 |
479 |
44 |
81 |
102 |
123 |
148 |
164 |
1000 |
313 |
358 |
397 |
415 |
441 |
463 |
475 |
45 |
84 |
102 |
128 |
150 |
163 |
Table 5. Female group mean body weight values and mean body weight gain.
Dose (mg/kg |
Group mean body weight |
Mean body weight gain |
|||||||||||||
Days after commencement of treatment |
Gestation days |
Lactation days |
Days after commencement of treatment |
Gestation days |
Lactation days |
||||||||||
0 |
7 |
14 |
0 |
7 |
14 |
20 |
1 |
4 |
7 |
14 |
7 |
14 |
20 |
4 |
|
0 |
203 |
214 |
229 |
240 |
280 |
321 |
396 |
300 |
317 |
11 |
26 |
40 |
81 |
157 |
17 |
40 |
201 |
214 |
226 |
241 |
279 |
316 |
385 |
297 |
315 |
13 |
25 |
38 |
75 |
144 |
18 |
200 |
204 |
218 |
231 |
241 |
280 |
316 |
389 |
296 |
313 |
14 |
27 |
39 |
76 |
149 |
17 |
1000 |
201 |
210 |
223 |
233 |
269 |
307 |
382 |
290 |
308 |
10 |
22 |
36 |
74 |
149 |
18 |
Table 6. Male group mean food consumption values.
Dose (mg/kg |
Days after commencement of treatment |
||||
7 |
14 |
28 |
35 |
41 |
|
0 |
28.1 |
28.1 |
27.1 |
28.5 |
28.1 |
40 |
28.8 |
28.3 |
26.4 |
28.0 |
27.7 |
200 |
27.8 |
27.8 |
27.1 |
27.7 |
27.5 |
1000 |
27.8 |
27.4 |
26.6 |
27.4 |
26.4 |
Table 7. Female group mean food consumption values.
Dose (mg/kg |
Days after commencement of treatment |
Gestation days |
Lactation days |
|||
7 |
14 |
7 |
14 |
20 |
4 |
|
0 |
17.9 |
18.4 |
23.9 |
26.6 |
27.1 |
32.8 |
40 |
18.1 |
18.8 |
23.5 |
25.8 |
25.8 |
32.4 |
200 |
18.2 |
18.8 |
24.3 |
26.2 |
26.5 |
32.1 |
1000 |
16.7 |
17.7 |
22.1 |
24.9 |
26.3 |
31.6 |
Table 8. Male mean haematology values.
Dose (mg/kg |
RBC Count (x10%L) |
HT (%) |
HB Conc (G/DL) |
Reticulocyte Count (%) |
MVC (m) |
MCH (PG) |
MCHC (%) |
Platelet Count (x10%L) |
WBC Count (x10%L) |
Differential count of leukocytes (% of total counted cells) |
|||||
Lymphocytes |
Neutrophils |
Eosinophils |
Basophile |
Monocytes |
|||||||||||
Segmented |
Band |
||||||||||||||
0 |
1001 |
47.0 |
15.4 |
17 |
46.9 |
15.4 |
32.7 |
74.1 |
120 |
93 |
3 |
0 |
1 |
0 |
4 |
40 |
993 |
46.6 |
15.4 |
12 |
46.9 |
15.6 |
33.0 |
76.7 |
107 |
94 |
2 |
0 |
1 |
0 |
3 |
200 |
968 |
45.7 |
15.0 |
21 |
47.2 |
15.5 |
32.9 |
75.1 |
109 |
88 |
5 |
0 |
1 |
0 |
5 |
1000 |
996 |
47.2 |
15.5 |
18 |
47.4 |
15.6 |
32.9 |
73.3 |
86 |
92 |
4 |
0 |
1 |
0 |
3 |
Table 9. Male group mean clinical chemistry values.
Dose (mg/kg |
GOT (IU/L) |
GPT (IU/L) |
GTP (IU/L) |
ALP (IU/L) |
Total Bilirubin (MG/DL) |
Urea Nitrogen(MG/DL) |
Creatinin (MG/DL) |
Glucose (MG/DL) |
Total Chol. (MG/DL) |
Triglyceride (MG/DL) |
Total Protein (G/DL) |
Albumin (G/DL) |
A/G Ratio |
Calcium (MG/DL) |
Inorganic Phos. (MG/DL) |
NA (MEQ/L) |
K (MEQ/L) |
CL (MEQ/L) |
0 |
88 |
30 |
0 |
245 |
0.11 |
18.1 |
0.6 |
129 |
60 |
67 |
6.76 |
3.97 |
1.43 |
9.2 |
7.8 |
143 |
4.4 |
103 |
40 |
83 |
28 |
0 |
264 |
0.06 |
19.5 |
0.5 |
149** |
68 |
67 |
6.77 |
3.99 |
1.44 |
9.1 |
7.6 |
143 |
4.5 |
103 |
200 |
76 |
26 |
0 |
232 |
0.05* |
17.3 |
0.6 |
135 |
64 |
50 |
6.63 |
3.92 |
1.45 |
9.0 |
7.5 |
143 |
4.3 |
103 |
1000 |
78 |
24 |
0 |
223 |
0.10 |
18.4 |
0.6 |
135 |
54 |
52 |
6.66 |
3.95 |
1.46 |
9.0 |
7.7 |
143 |
4.3 |
103 |
*: Significantly different from control value, * P<0.05; ** P<0.01
Table 10. Group mean absolute and relative organ weight values.
Dose (mg/kg |
Male (group mean absolute organ weight) |
Male (group mean relative organ weights) |
Female (group mean absolute organ weight) |
Female (group mean relative organ weight) |
||||||||||||||
Final Body weight (g) |
Thymus (mg) |
Liver (g) |
Kidneys (g) |
Testes (g) |
Epididymides (g) |
Thymus (x10-3) |
Liver |
Kidneys |
Testes |
Epididymides |
Final Body weight (g) |
Thymus (mg) |
Liver (g) |
Kidneys (g) |
Thymus (x10-3) |
Liver |
Kidneys |
|
0 |
461 |
359 |
12.57 |
3.07 |
3.24 |
1.21 |
78 |
2.72 |
0.67 |
0.71 |
0.26 |
317 |
256 |
12.79 |
1.98 |
81 |
4.04 |
0.63 |
40 |
456 |
375 |
12.65 |
3.04 |
3.37 |
1.28 |
82 |
2.77 |
0.67 |
0.74 |
0.28 |
315 |
279 |
12.61 |
2.03 |
88 |
4.01 |
0.65 |
200 |
455 |
327 |
12.19 |
2.89 |
3.18 |
1.18 |
72 |
2.68 |
0.64 |
0.70 |
0.26 |
313 |
231 |
12.48 |
1.88 |
73 |
4.00 |
0.60 |
1000 |
451 |
366 |
12.41 |
2.97 |
3.14 |
1.18 |
80 |
2.75 |
0.66 |
0.70 |
0.26 |
308 |
244 |
12.91 |
1.98 |
79 |
4.20 |
0.65 |
Applicant's summary and conclusion
- Conclusions:
- Daily repeat oral gavage doses of 1,2-butanediol at 40, 200, and 1000 mg/kg were administered to rats (males) from 14 days prior to mating and during the mating period and thereafter for a total of 42 days and to females from 14 days prior to mating and during the period covering mating, gestation, and delivery until lactation day 3 did not result in adverse effect. Therefore, the no observed effect levels (NOEL) under the experimental conditions used were considered 200 mg/kg for repeat dose toxicity and 1000 mg/kg for reproductive and developmental toxicity while the no observed adverse effect levels of 1000 mg/kg for repeat dose toxicity and > 1000 mg/kg for reproductive and developmental toxicity.
- Executive summary:
OECD 422 - Daily repeat oral gavage doses of 1,2-butanediol at 40, 200, and 1000 mg/kg were administered to SD rats. The test article was orally administered once daily to males from 14 days prior to mating and during the mating period and thereafter for a total of 42 days and to females from 14 days prior to mating and during the period covering mating, gestation, and delivery until lactation day 3. Toxicological effects on parent animals and effects on reproductive performance, such as gonadal function, mating behaviour, fertility, delivery, and lactation were investigated.
No mortality was observed, body weight, food consumption, haematology and organ weight were unaffected throughout the study. For glucose in the 40 mg/kg group and total bilirubin in the 200 mg/kg group, statistical differences were noted. However, no related changes suggestive of the effects of the test article were noted.
In females of the 1000 mg/kg group, post-treatment decreases in locomotor activity were observed in more than half of the animals and hypopnea in a few animals. Both signs were transient in nature. The number of affected animals decreased over time, and on day 6 or later, the sign occurred only in one animal until gestation day 5 (at 21 days after the commencement of treatment). No abnormalities occurred in males. In addition, hair loss was observed in one female of the 1000 mg/kg group, but the finding is considered a spontaneous finding.
Bilateral atrophy of the testes was found in one male of the 1000 mg/kg group (animal number: DM09), this was reflected by extensive atrophy of seminiferous tubules found in histopathology and associated with slight bilateral atrophy of the epididymides. In the testes, degeneration, vacuolation, and multinucleate cell formation were observed in the sperm cells, but no abnormalities were observed in Sertoli cells or interstitial cells. In the other animals, including those of the 40 and 200 mg/kg groups, no abnormalities were found in the testes or epididymides. The other changes included germinal centre deficiency in the spleen and unilateral extensive hemorrhagic necrosis in the adrenal cortex in one female of the 1000 mg/kg group (D07).
In both the control group and 1000 mg/kg group, focal myocardial degeneration in the heart, microgranuloma in the liver, fatty change of hepatocytes, and brown pigmentation in tubular epithelial cells, cyst, focal basophilic change in renal tubules and fatty change of tubular epithelia in the kidneys were sporadically found. No between-group differences in the incidences of these changes were noted; therefore, these changes were not indicative of the treatment effects. In addition, in females, slight increases of hematopoietic cells in the spleen and diffuse chronic hypertrophy in the fascicular zone of the adrenals were found in almost all animals in the control and 1000 mg/kg groups without any between-group differences.
Reproductive performance for both males and females, no abnormality was noted in copulation index or fertility index, and no effect of the test article was noted in gestation length, delivery, or nursing behaviour. Furthermore, the examination on corpora lutea count, implantation site count, implantation index, gestation index, delivery index, offspring count, and viable offspring count revealed no changes suggestive of effects of the test article on ovulation, implantation, or subsequent embryonic development. In addition, no abnormality was noted in the external surface of the offspring, viability index, bodyweight at birth, or bodyweight gain after birth. In necropsy of neonates, thymic remnant in the neck and left umbilical artery were sporadically found. However, these findings were those often spontaneously observed at the end of the fetal stage, and the incidences were not correlated with dose levels. In one female of the 1000 mg/kg group, (a) white spot(s) was(were) found, which was (were) hepatic necrosis and fatty change. These changes are known to be induced by various factors, and it is widely recognised that these changes are also induced by circulatory impairment and metabolic disorder including nutritional disorder. In this study, however, the changes occurred in only one animal and were not found in the other neonates; therefore, they were not considered treatment related.
Therefore, the no observed effect levels (NOEL) under the experimental conditions used were considered 200 mg/kg for repeat dose toxicity and 1000 mg/kg for reproductive and developmental toxicity while the no observed adverse effect levels of 1000 mg/kg for repeat dose toxicity and > 1000 mg/kg for reproductive and developmental toxicity.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.